cyclohexanol has been researched along with fingolimod hydrochloride in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cassidy, MP; He, H; Milstien, S; Paugh, SW; Selley, DE; Sim-Selley, LJ; Spiegel, S | 1 |
1 other study(ies) available for cyclohexanol and fingolimod hydrochloride
| Article | Year |
|---|---|
Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Topics: Animals; Benzoxazines; Binding, Competitive; Cell Line; CHO Cells; Cricetinae; Cricetulus; Cyclohexanes; Cyclohexanols; Endocytosis; Enzyme Activation; Fingolimod Hydrochloride; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Immunosuppressive Agents; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Morpholines; Naphthalenes; Phenols; Piperidines; Propylene Glycols; Proto-Oncogene Proteins c-akt; Pyrazoles; Radioligand Assay; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Sphingosine | 2006 |